Madrigal Pharmaceuticals Inc. (MDGL) presented its Q2 2026 performance and commercial progress at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026. The company’s lead drug, Rezdiffra, generated $364 million in sales, marking steady growth as it surpassed 50,000 patients on therapy—crossing that threshold in July 2026. Net patient additions averaged 6,000 to 7,000 per quarter, reflecting robust market penetration in the metabolic and liver disease space. Trading at $525.27 after a 3.91% drop from the prior close of $546.66, MDGL remains in focus amid its commercialization efforts and pipeline development.
Madrigal Pharmaceuticals Highlights Q2 Growth, Pipeline Expansion at Conference
Rezdiffra sales hit $364 million with over 50,000 patients on therapy, while a $300 million pipeline includes Phase II studies for three assets.
PA
Priya Anand · Equities & Earnings Desk · 22 Sept 2026 · 05:49 · 1 min readThis article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
